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Abstract
Summary End-stage renal disease (ESRD) patients have a
high risk of fractures. We evaluated bone microstructure and
finite-element analysis-estimated strength and stiffness in
patients with ESRD by high-resolution peripheral computed
tomography. We observed an alteration of cortical and tra-
becular bone microstructure and of bone strength and stiffness
in ESRD patients.
Introduction Fragility fractures are common in ESRD patients
on dialysis. Alterations of bone microstructure contribute to
skeletal fragility, independently of areal bone mineral density.
Methods We compared microstructure and finite-element
analysis estimates of strength and stiffness by high-resolution
peripheral quantitative computed tomography (HR-pQCT) in
33 ESRD patients on dialysis (17 females and 16 males; mean
age, 47.0±12.6 years) and 33 age-matched healthy controls.
Results Dialyzed women had lower radius and tibia cortical
density with higher radius cortical porosity and lower tibia
cortical thickness, compared to controls. Radius trabecular
number was lower with higher heterogeneity of the trabecular
network. Male patients displayed only a lower radius cortical
density. Radius and tibia cortical thickness correlated nega-
tively with bone-specific alkaline phosphatase (BALP). Mi-
crostructure did not correlate with parathyroid hormone
(PTH) levels. Cortical porosity correlated positively with
“Kidney Disease: Improving Global Outcomes” working
group PTH level categories (r00.36, p<0.04). BMI correlated
positively with trabecular number (r00.4, p<0.02) and nega-
tively with trabecular spacing (r0−0.37, p<0.03) and trabec-
ular network heterogeneity (r0−0.4, p<0.02). Biomechanics
positively correlated with BMI and negatively with BALP.
Conclusion Cortical and trabecular bone microstructure and
calculated bone strength are altered in ESRD patients, pre-
dominantly in women. Bone microstructure and biomechani-
cal assessment by HR-pQCT may be of major clinical
relevance in the evaluation of bone fragility in ESRD patients.
Keywords Bone microarchitecture . Chronic kidney
disease . Dialysis . High-resolution peripheral quantitative
computed tomography
Introduction
Chronic kidney disease (CKD) affects 10 % of the popula-
tion and is associated with alterations in bone and mineral
metabolism. In up to 75–100 % of patients, bone disease
occurs when the glomerular filtration rate (GFR) falls below
60 ml/min per 1.73 m2 and is commonly referred to as renal
osteodystrophy or, more recently, chronic kidney disease–
mineral bone disease (CKD–MBD) [1, 2]. Several types of
disorders can be observed, ranging from high-turnover
(hyperparathyroidism) to low-turnover bone lesions (ady-
namic bone). In addition to renal failure, CKD–MBD may
be worsened from a combination of various factors such as
vitamin D deficiency, hyperparathyroidism, malnutrition,
the use of certain drugs (corticosteroids, phosphate binders,
vitamin D analogs), or hypogonadism [3]. It is associated
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also with increased morbidity (vascular lesions, fractures,
cardiovascular events) and higher mortality [4, 5].
Compared to a normal population, fracture occurrence is
higher in CKD patients at all skeletal sites, e.g., hip, verte-
bral, wrist, as soon as GFR falls below 60 ml/min per
1.73 m2 [6, 7]. In dialyzed patients (end-stage renal disease,
ESRD), there is a fourfold increased risk of hip fracture [8]
that positively correlates with age, duration of dialysis, low
parathyroid hormone (PTH) levels [9], female gender, low
body mass index (BMI), presence of peripheral vascular
disease, and tobacco abuse [8].
Histomorphometric analysis of bone biopsy specimens
after double tetracycline labeling assesses bone microstruc-
ture and turnover, but is limited by the invasiveness of the
procedure [10]. Dual X-ray absorptiometry (DXA) meas-
ures areal bone mineral density (aBMD), which is a predic-
tor of fracture risk in osteoporosis and CKD–MBD [11].
However, DXA is unable to analyze bone microstructure,
cannot easily differentiate between cortical and trabecular
bone, and is influenced by artefactual vascular calcification
projections, particularly at the lumbar spine level. Micro-
structure alterations contribute to bone fragility, irrespective
of aBMD [12, 13].
High-resolution peripheral quantitative computed to-
mography (HR-pQCT) is a noninvasive procedure that
discriminates between trabecular and cortical bone and
quantitatively evaluates microstructure variables, includ-
ing cortical porosity (CtPo), with a 82-μm-voxel resolu-
tion. CT datasets from individual scans can be used for
microstructural finite-element analysis (FEA) to assess
bone mechanical competence (failure load and stiffness).
Few studies have evaluated hemodialysis patients with
these techniques [14, 15], but they indicate an alteration
of both cortical and trabecular bone compartments in
relation to the severity of secondary hyperparathyroidism.
The aim of this study was to analyze bone 3D microstructure,
CtPo, and biomechanical properties in both compression
(FEA) and torsion (polar moment of inertia) by HR-pQCT
in ESRD patients compared to age-, gender-, and weight-
matched healthy controls.
Patients and methods
Subjects
Subjects consisted of 33 individuals on chronic dialysis (16
men and 17 women, 9 postmenopausal and 8 premenopausal;
median age, 50.4 (interquartile range, 16.7 years)) recruited at
the Geneva University Hospitals, Geneva, Switzerland. Inclu-
sion criteria were >18 years and hemodialysis (n026) or
peritoneal dialysis (n07) for more than 3 months. Exclusion
criteria were previous treatment with bisphosphonates, other
metabolic diseases with an impact on bone (e.g., Paget dis-
ease, osteogenesis imperfecta), pregnancy, or previous renal
transplant with a graft survival of more than 3 months.
Patients were hemodialyzed three times a week during 4 h
using a dialysate calcium concentration of 1.5 mmol/l. The
dialysate calcium concentration of patients on peritoneal
dialysis was 1.25 mmol/l.
Patients were categorized according to the PTH level
defined in the Kidney Disease: Improving Clinical Out-
comes (KDIGO) recommendations [16]: low bone turnover
for intact PTH levels lower than 13.6 pmol/l (twice the
upper normal limit of the assay), normal bone turnover for
intact PTH levels between 13.6 and 61.2 pmol/l (nine times
the upper normal limit), and high bone turnover for intact
PTH above 61.2 pmol/l, based on a mean PTH value of two
samples measured at 3-month intervals.
Patients were compared to 33 age-, gender-, and weight-
matched healthy controls. Women were also matched accord-
ing to their menopausal status. Controls were recruited mainly
among the hospital staff and their families, per personal con-
tact and advertisement. To compute the patient T-score, we
studied also 83 young healthy individuals (58 females and 25
males; mean age, 22.7±3.8 years) recruited during the same
period, i.e., a population at peak bone mass. The protocol was
approved by the ethics committee of Geneva University Hos-
pitals, and written informed consent was obtained from each
patient and healthy subject.
Clinical assessment
Height was determined by a Holtain stadiometer (Holtain,
Crosswell, Wales). Weight was determined on a calibrated
scale to the nearest 0.1 kg. BMI was calculated from weight-
to-height ratio (in kilogram/height in meters squared). Cal-
cium and protein intakes were recorded by a validated food
frequency questionnaire [17]. Family history of fracture,
tobacco use, alcohol intake, medical history, presence and
type of atraumatic fracture, and presence, type, indication,
and dose of prior treatment potentially influencing bone
metabolism were determined in all subjects. The age at last
menses defined menopausal age and was determined in all
postmenopausal women; menopause was of physiological
origin in all patients. Time since first dialysis at inclusion
was computed. Nutritional status was determined using the
mini-nutritional assessment short form (MNA-SF) [18],
which includes six items (appetite, weight loss, mobility,
acute disease or psychological stress, cognitive dysfunction
or depression, and BMI). Dialysis parameters Kt/V (fractional
urea clearance controlled for volume of distribution) and
percent reduction of urea (PRU) were used to evaluate the
efficacy of dialysis [19]. Frequency and time of dialysis [20],
as well as calcium and bicarbonate dialysate concentrations,
were recorded.
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Areal BMD assessment
aBMD at the level of the lumbar spine (LS) in antero-posterior
view, femoral neck, and total hip was measured byDXA using
a Hologic QDR 4500 instrument (Hologic, Inc., Waltham,
MA, USA). The coefficient of variation of repeated BMD
measurements was 1–2 % [21, 22]. BMD (in gram per square
centimeter) was also expressed as a T-score, which compares
individual BMD values with those of a young normal popu-
lation of the same gender (number of standard deviations from
the mean) [23], using the 3rd National Health and Nutrition
Examination Survey or HOLOGIC database [23]. Vertebral
fracture prevalence was evaluated by DXA-based vertebral
fracture assessment [24].
High-resolution peripheral quantitative computed
tomography assessment
Volumetric bone density and cortical and trabecular micro-
structure were determined at the nondominant distal radius in
28 of 33 (21 of 26, hemodialysis; 7 of 7, peritoneal dialysis)
patients using a HR-pQCT instrument (XtremeCT, Scanco
Medical AG, Bruettisellen, Switzerland) as previously de-
scribed [12, 25]. The dominant arm was measured in five
patients, given the presence of arterio-venous fistula on the
nondominant one. Tibia data were obtained on ipsilateral tibia
except for patients with dominant radius data. The system uses
a 2D detector array in combination with a 0.08-mm point-
focus X-ray tube, enabling the simultaneous acquisition of a
stack of parallel slices with a nominal resolution (voxel size)
of 82 μm. The following settings were used: effective tension
of 60 kVp, X-ray tube current of 900 μA, and matrix size of
1,536×1,536. At each acquisition site, 110 slices were
obtained, leading to a 3D representation of approximately
9 mm in the axial direction. All examinations were analyzed
by the same observer. The radiation effective dose was 3 μSv
per measurement with an acquisition time of 3 min. The
reproducibility of HR-pQCT at the distal tibia was assessed
in 15 healthy subjects (with repositioning) and varied from 0.7
to 1.0 % and from 3.0 to 4.9 % for bone density and for
trabecular architecture, respectively [26]. These reproducibil-
ity data ranges are similar to those previously published with
the same device [12]. The reproducibility of the FE-calculated
stiffness and strength was better than 3.3 % and is very similar
to values reported for the reproducibility of morphological
measures of the same data set (Bert Van Rietbergen et al.,
personal communication).
The following variables were recorded [25]: total (Dtot),
cortical (Dcort), and trabecular (Dtrab) volumetric density,
expressed as milligram hydroxyapatite-equivalent per cu-
bic centimeter; relative trabecular bone volume fraction
(BV/TV, in percent); trabecular number (TbN); trabecular
thickness (TbTh, in micrometer); trabecular separation
(TbSp, in micrometer); heterogeneity of the trabecular net-
work (TbSp.SD); cross-sectional area (CSAtotal, in square
millimeter); cortical thickness (CTh, in millimeter), and CtPo
(in percent) [27]. CtPo was quantified using customized anal-
ysis tools [27–29] and calculated as the number of void voxels
within the cortex. BV/TV is derived from Dtrab assuming that
fully mineralized bone has a mineral density of 1,200 mg
HA/cm3. TbN was defined as the inverse of the mean spacing
of the mid-axes. TbTh and TbSp were derived from BV/TV
and TbN using standard histomorphometricmethods. TbSp.SD
was evaluated by measuring the standard deviation of the
individual distribution of the TbSp. The system provides a
direct assessment of cortical bone density. CTh is defined as
the mean cortical volume divided by the outer bone surface.
High-resolution peripheral quantitative computed
tomography image-based biomechanical analysis
FEA of HR-pQCT scans was used to calculate biomechanical
properties relevant for compression. We generated finite-
element models directly from the 3D HR-pQCT image data
using the voxel-conversion approach [30–32]. Outcomes in-
cluded stiffness (in newton per millimeter), calculated as the
reaction force (RFz) determined by the FEA divided by the
applied displacement, and estimated failure load (in newton)
using the Pistoia criterion [32]. We determined also the per-
centage of the total load that is carried by trabecular bone at
the most distal slice and the apparent modulus, which was
defined as the reaction force divided by the projected cross-
sectional area and the applied longitudinal strain [33].
To quantify the stiffness of the bone for torsion loading,
the polar moment of inertia was calculated using the man-
ufacturer's software.
Biochemical data
Plasma calcium, phosphate, total CO2, and creatinine were
measured with an automatic analyzer (Beckman Coulter
DxC800; Beckman Coulter, Inc, Orange County, CA, USA).
Plasma calcium was adjusted for albumin levels (adjusted Ca0
Ca+[0.02×(40-albumin)]). Serum PTH and osteocalcin were
measured using a two-site chemiluminescent immunometric
assay (Elecsys R, Roche, Basel, Switzerland). Bone-specific
alkaline phosphatase (BALP) was measured by enzyme im-
munoassay (Beckman Coulter I800). Insulin growth factor I
(IGF-I) was measured by enzyme-labeled chemiluminescent
immunometric assay (Siemens Immulite 2500; Siemens
Healthcare Diagnostics Inc, Tarrytown, NY, USA).
Statistics
Results are presented as the means ± standard deviation.
When the clinical and biological data were not normally
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distributed, descriptive statistics are given as the median and
95 % confidence interval (CI). Normality was verified by
using Shapiro–Francia tests. Comparisons between ESRD
patients and age-matched controls for continuous varia-
bles were performed with a Wilcoxon matched-pairs
signed-ranks test to take into account the matched design.
Comparisons between ESRD patients and young healthy
controls were performed with a Kruskal–Wallis equality-
of-populations rank test. Chi-squared tests were used for
comparing proportions.
Correlations between HR-pQCT parameters and varia-
bles were determined by Spearman rank correlation for
non-normally distributed variables. The significance level
for two-sided p values was 0.05 in all tests. All statistical
analyses were performed using STATA software (version
11.0; Stata Corporation, College Station, TX, USA).
Results
Patient characteristics
The 33 patients with ESRD (16 men and 17 women, nine of
them being postmenopausal) were 47.0±12.6 years old.
Median time of dialysis was 0.95 years (95 % CI, 0.75–
2.30 years). Table 1 reports the leading causes of renal
failure. No patient had a family history of fragility fracture.
Five patients (15 %) reported a history of low-trauma clin-
ical fracture (four females and one male); four occurred
before initiation of dialysis (three females and one male),
and all were non-vertebral. Dialysis patients and control
subjects did not differ in age, weight, or BMI, but patients
were 2±5 % shorter compared to matched controls (Table 1).
According to the KDIGO recommendations for PTH levels
in ESRD patients [16], 25 patients were in the targeted
values (PTH between 13.6 and 61.2 mmol/l), four had low
PTH values (PTH under 13.6 mmol/l), and four had elevated
values (PTH superior to 61.2 mmol/l) (Table 1).
Regarding concomitant medications affecting bone me-
tabolism (Table 1), among patients receiving at least one
medication, 13 (39 %) were treated with only a phosphate
binder (calcium acetate or carbonate and/or sevelamer) and
2 with calcitriol as unique medication. Eight received a
combination of a phosphate binder and calcitriol. Three
patients were treated with the association of a phosphate
binder and cinacalcet. Finally, two received a binder with
cinacalcet and calcitriol in combination.
Areal BMD comparisons between patients, matched control,
and young healthy population
Compared with young healthy individuals and matched
controls, ESRD women had lower lumbar spine and hip
aBMD (Table 2). In men, lumbar spine aBMD was signif-
icantly higher compared with matched controls. Hip aBMD
was no different from control values. Prevalence of osteo-
penia and osteoporosis at any site was 52 % (17 of 33) and
15 % (5 of 33) in ESRD patients, and 48 % (16 and 33) and
6 % (2 and 33) in age-matched controls, respectively (not
significantly different). Eleven patients (33 %) and 15
(58 %) controls had normal DXA values. Femoral neck
BMD T-score in patients with fracture tended to be lower
than in those observed without fracture, but this difference
did not reach statistical significance (−1.8±1.0 in those with
a fracture vs −1.2±1.1 in unfractured patients, p00.17).
Vertebral fracture assessment identified three silent vertebral
fractures in patients without a clinical history of clinical
fracture. Vertebral body height reduction was between 20
and 25 % in two patients and between 25 and 40 % in one
patient.
Comparisons of vBMD and microstructural parameters
between patients and controls
ESRD women had lower total and cortical densities at both
sites compared with age-matched controls (−12 and −7 %
for both distal radius and tibia, respectively, p<0.01; Table 3).
Lower cortical density was associated with a higher po-
rosity at the radius level (+82 %; p<0.05) and a lower
CTh at the tibia (−12 %; p<0.05; Table 3). In women,
there were also alterations of the trabecular compartment
with a lower TbN (−12 %; p<0.05) and a higher hetero-
geneity of the TbSp.SD at the radius (+43 %; p<0.05). At
the tibia, trabecular density was 11 % lower (p<0.05).
Compared with young healthy controls, both distal radius
and distal tibia cortical and trabecular compartment vari-
ables were lower (Table 3). In contrast to the DXA find-
ings, male ESRD patients displayed a 7 % lower radius
cortical density (p<0.01; Table 4). Compared with young
male healthy controls, lower values in cortical density and
thickness and in trabecular variables were mostly detected
at the distal tibia and not at the distal radius.
FEA and polar moment of inertia
As determined by FEA, stiffness and predicted failure
load at both distal radius and tibia were lower in ESRD
women, but not in men, compared with age-matched controls
(Table 5).
Relationship of aBMD, bone microstructural parameters,
cortical porosity, and bone strength with demographic,
dialysis, nutritional, and biological parameters
Using Spearman rank correlation analysis, we examined
the relationship between aBMD, microstructural bone
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parameters, bone strength and time on dialysis, nutri-
tional parameters (MNA-SF, daily calcium and protein
intake, and plasma IGF-I used as a reflection of nutritional
status), biological parameters including PTH, and bone for-
mation markers (BALP, osteocalcin) (Table 6). Lumbar spine
and total hip BMD positively correlated with BMI and MNA-
SF, while lumbar spine BMD correlated negatively with
BALP (p<0.003).
Distal radius cortical volumetric density and CTh corre-
lated negatively with BALP. Distal radius cortical volumet-
ric density was positively associated with MNA-SF. Radius
CtPo was positively associated with KDIGO PTH level
categories (r00.36; p<0.03) (data not shown). There was
no association between radius bone microstructural param-
eters and other dialysis or biological parameters. The per-
centage of load carried by trabecular bone at the distal radius
Table 1 Characteristics of the
subjects
Results are means ± standard
deviation for Gaussian
continuous variables
N Normal range, MNA-SF mini-
nutritional assessment short form,
PRU percent reduction of urea
*p<0.05: dialyzed patients com-
pared with matched controls
aVascular disease includes vascu-
litis, thromboembolic disease,
hemolytic–uremic syndrome
or thrombotic thrombocytopenic
purpura, hypertension, scleroder-
ma, unilateral or bilateral renal
artery stenosis, and cholesterol
atheroembolic disease
bCongenital renal anomalies
includes aplasia, hypoplasia,
and dysplasia. Patients may
have multiple causes
cFractional urea clearance con-
trolled for volume of distribution
for hemodialyzed patients
ESRD patients Matched
controls
Young
controls
Number 33 33 83
Gender (M/F) 16/17 16/17 25/58
Number of menopausal women 9 9 0
Age (years) 47±13 48±13 23±4
Age of men (years) 48±12 51±14 27±4
Age of women (years) 46±13 46±12 21±2
Weight (kg) 71±18 68±12 63±12
Height (cm) 166±11* 169±9 169±9
BMI (kg/m2) 25±5 24±3 22±3
Main causes of renal failure, n (%)
Chronic glomerulonephritis 8 (24)
Polycystic kidney disease 1 (3)
Vascular diseasea 14 (42)
Tubular and interstitial diseases 1 (3)
Diabetes 5 (15)
Congenital renal anomaliesb 1 (3)
Other or unknown 6 (18)
MNA-SF (n≥12/14) (median, 95 % CI) 12 [11-13]
Concomitant medications affecting bone
No treatment, n (%) 6 (18)
Phosphate binders, n (%) 25 (76)
Calcitriol, n (%) 11 (33)
Cinacalcet, n (%) 5 (15)
Protein intake (g daily) 61±22
Protein intake per kg (g/kg daily) 0.9±0.3
Calcium intake (mg daily, median, 95 % CI) 614 [564–725]
Peritoneal dialysis (n) 7
Kt/Vc 1.6±0.3
PRU (%, median, 95 % CI) 75 [71–79]
Time on dialysis (years) (median, 95 % CI) 0.9 [0.8–2.3]
Creatinine [N, 35–106 μmol/l] 843±291
Albumin corrected calcium [N, 2.25–2.60 mmol/l] 2.30±0.17
Serum phosphate [N, 0.80–1.4 mmol/l] 1.73±0.48
Total plasma CO2 [N, 23–30 mmol/l] 22.9±3.1
Serum PTH [N, 1.1–6.8 pmol/l] 40±31
Serum IGF-I [N, 116–447 ng/ml] 200±80
Serum osteocalcin (median, 95%CI; N, 8.8–29.7 μg/l) 281 [95 % CI 147–329]
Bone-specific alkaline phosphatase
(median, 95 % CI) [N, 2.9–22.6 mmol/l]
16 [95 % CI 13–24]
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increased with the BALP serum level (r00.36; p00.05) and
was negatively associated with the MNA-SF score (r0−0.41;
p00.02) (data not shown).
Distal tibia cortical thickness was negatively associated
with BALP (r0−0.37; p00.04). A positive association was
observed between cortical volumetric density and MNA-SF
(p00.02). TbN correlated positively with BMI (p<0.02),
while TbSp (p<0.03) and the TbSp.SD (p<0.02) correlated
negatively with BMI. There was no association between
tibia bone microstructural parameters and dialysis, nutritional
status, and other biological parameters. At the distal tibia, a
negative association with BALP was observed for stiffness
(r0−0.40; p00.03), predicted failure load (r0−0.40; p00.03),
and the cortical polar area moment of inertia (r0−0.46;
p<0.01). Stiffness and predicted failure load were positively
associated with BMI (p<0.05).
In order to delineate the structural effects and the resulting
consequences on bone strength of a presumably low-turnover
bone disease, we categorized the patients into two groups
according to PTH levels: lower than 13.6 pmol/l which is
the lower threshold for PTH values according to the KDIGO
recommendations (two times the upper limit of normal values)
and higher. Only four patients had such low PTH values. We
compared the two populations and found that the group with
the lower PTH level had a lower cortical porosity at the radius
level (p<0.03).
Relationship of aBMD and bone microstructural parameters
We wanted to study whether and to what extent aBMD cor-
related with bone microstructural parameters assessed by HR-
pQCT. We limit our analysis to variables directly measured
and not derived from calculation. Areal BMD at LS and total
hip were correlated with trabecular density (r00.44 to 0.56,
p<0.05) at either the radius or the tibia. Cortical density was
not correlated to aBMD at any site. The cross-sectional area
was highly correlated at the LS and total hip levels with r
values ranging from 046 to 0.53 (p<0.05).
Discussion
The present study shows that the use of HR-pQCT to
evaluate bone microstructure, CtPo, and estimates of bone
strength and stiffness by FEA allows to detect alterations in
densitometric and microstructural variables that may con-
tribute to an increased fracture risk in ESRD patients beyond
those identified by DXA-determined aBMD. The main find-
ings are: (1) In ESRD women who seem to be more affected
than men, there is a marked increase in the heterogeneity of
the trabecular network and of cortical porosity, particularly
at the distal radius level, and a lower distal tibia cortical
thickness. (2) The decrease of bone density and microstruc-
tural alterations found in ESRD women are associated with
lower calculated bone strength and stiffness at both skeletal
sites. (3) Although dialyzed male patients have lower corti-
cal and trabecular variables predominantly at the tibia com-
pared to the young healthy population, only a lower radius
cortical density was statistically significant when compared
to age-matched controls with similar aBMD values. (4)
Among the recorded factors, nutritional and anthropometric
variables, as well as bone turnover, determine the differ-
ences in cortical and trabecular microstructural parameters
and in bone strength and stiffness in ESRD patients. Cortical
porosity is related to KDIGO categories of PTH levels.
To assess bone structural characteristics, several studies
with pQCT have been conducted in patients with CKD or
ESRD. The first studies used instruments with a 350-μm
resolution and showed a lower cortical vBMD, but no
significant differences in trabecular BMD in ESRD patients
[34–36] compared with healthy controls. A recent cross-
sectional study in 52 adults on maintenance hemodialysis
demonstrated that reductions in pQCT values of the radius
cortical bone were strongly predictive of vertebral and fra-
gility peripheral fractures, but not pQCT trabecular vBMD
and DXA aBMD [37].
Studies with HR-pQCT in non-CKD subjects have
shown that alterations of cortical and trabecular structures
Table 2 Areal BMD in patients,
matched controls, and young
healthy individuals
SD standard deviation
*p<0.05 as compared with age-,
weight-, and gender-matched
controls; **p<0.01 as compared
with young healthy controls
ESRD patients Matched controls Young controls
BMD (g/cm2) T-score (SD) BMD
(g/cm2)
T-score (SD) BMD
(g/cm2)
T-score
(SD)
Women
Spine 0.92±0.1*,** −1.1 (1.0) 1.02±0.1 −0.1 (1.0) 1.03±0.1 −0.1 (1.2)
Femoral neck 0.65±0.1*,** −1.8 (1.2) 0.75±0.1 −0.9 (0.8) 0.84±0.1 −0.1 (1.1)
Total hip 0.78±0.2*,** −1.3 (1.3) 0.86±0.1 −0.6 (0.7) 0.93±0.1 −0.1 (1.1)
Men
Spine 1.09±0.1* −0.1 (0.8) 0.96±0.1 −1.2 (1.1) 1.02±0.1 −0.7 (0.9)
Femoral neck 0.83±0.1 −0.7 (0.9) 0.81±0.1 −0.9 (1.0) 0.91±0.1 −0.1 (1.0)
Total hip 0.98±0.1 −0.4 (0.8) 0.99±0.1 −0.3 (0.9) 1.04±0.12 0.0 (0.8)
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are associated with fragility fractures, partially independent
of decreased aBMD [13]. Similarly, vertebral fractures are
associated with low vBMD and architectural decay of tra-
becular and cortical bone at the radius and tibia, independent
of spine aBMD [38]. In CKD–MBD patients, HR-pQCT has
been applied in predialysis chronic kidney disease patients
>50 years [39]. In this study, patients with predialysis CKD
and fractures had lower DXA-determined aBMD and lower
vBMD, thinner cortices, and lower TbN than subjects with-
out fractures. In another study, both aBMD and HR-pQCT
parameters were associated with fractures among men and
women with stages 3–5 CKD not on dialysis. The variable
that discriminated between fractured and non-fractured
patients was ultradistal radius aBMD. This variable was
more predictive than any HR-pQCT parameter, and the
addition of HR-pQCT results to ultradistal radius aBMD
did not improve fracture discrimination [11]. In dialysis
patients, Negri et al. [14] found a marked decrease in corti-
cal density, thickness, and area, together with reductions in
trabecular parameters in both men and women. However,
these changes correlated with the severity of secondary
hyperparathyroidism in women only. These findings are in
Table 3 Volumetric BMD, microstructural parameters, and cortical porosity in women and matched controls
ESRD patients Matched controls Young controls
Value T-score Value T-score % Difference
(95 % CI)
Value
Radius Dtot (mg/cm3) 280±48***,** −0.8±0.8 331±78 0.1±1.4 – 12 % (−24; −4) 327±57
Dcort (mg/cm3) 859±90**** −0.7±1.9 928±58 0.7±1.2 – 7 % (−11; 1) 893±47
C.Th (mm) 0.7±0.2* −0.6±1.1 0.8±0.2 0.1±1.1 – 12 % (−24; 4) 0.8±0.2
Dtrab (mg/cm3) 120±41** −1.1±1.1 148±34 −0.3±0.9 – 14 % (−39; 10) 160±37
BV/TV (%) 10±3** −0.9±1.1 12±3 −0.2±0.9 – 13 % (−36; 10) 13±3
TbN (n/mm) 1.6±0.3***,** −1.4±1.2 1.9±0.2 −0.3±1.0 – 12 % (−27; −3) 2.0±0.2
TbTh (mm) 0.06±0.01** −1.0±1.4 0.07±0.01 −0.5±1.1 – 5 % (−17; 16) 0.07±0.01
TbSp (mm) 0.57±013***,** 1.7±1.8 0.47±0.06 0.3±0.9 24 % (2; 46) 0.44±0.07
CSAtotal (mm2) 242±33 −0.2±0.7 256±40 0.1±0.9 – 3 % (−17; 3) 252±44
TbSp.SD 0.27±0.09***,** 2.4±2.3 0.20±0.04 0.6±1.1 43 % (5; 75) 0.18±0.04
Cortical porosity (%) 2.9±3.9*** – 1.1±0.6 – 82 % (−6; 215)a NA
Cortical pore diameter (mm) 0.17±0.04 – 0.15±0.02 – 16 % (−7; 29) NA
Tibia Dtot (mg/cm3) 238±36***,** −1.6±0.7 280±54 −0.9±1.0 – 12 % (−30; 3) 328±55
Dcort (mg/cm3) 855±93****,** −2.4±2.9 923±54 −0.3±1.7 – 7 %(−11; −1.1) 932±32
CTh (mm) 0.9±0.2***,** −1.3±1.1 1.1±0.2 −0.5±1.0 – 12 % (−27; −2) 1.2±0.2
Dtrab (mg/cm3) 124±31***,** −1.6±0.9 144±29 −1.1±0.8 – 11 % (−20; −8) 182±36
BV/TV (%) 10±3***,** −1.5±0.9 12±3 −1.0±0.8 – 10 % (−25; −8) 15±3
TbN (n/mm) 1.6±0.3** −0.9±1.0 1.7±0.3 −0.5±1.0 – 5 % (−20; 14) 1.9±0.3
TbTh (mm) 0.07±0.01** −1.3±1.2 0.07±0.01 −0.9±1.1 – 4 % (−25; 17) 0.08±0.01
TbSp (mm) 0.59±0.12** 1.3±1.4 0.53±0.11 0.7±1.2 16 % (−10; 25) 0.47±0.09
CSAtotal (mm2) 662±102* 0.5±0.9 667±116 0.6±1.0 3 % (−14; 14) 604±113
TbSp.SD 0.29±0.08** 2.2±2.1 0.25±0.08 1.3±1.9 24 % (−14; 61) 0.20±0.04
Cortical porosity (%) 7.0±6.5 – 3.9±2.5 – 41 % (−8; 141)a NA
Cortical pore diameter (mm) 0.19±0.03 – 0.18±0.02 – 4 % (−5; 14) NA
Values are means±SD. Total (Dtot), cortical (Dcort), and trabecular (Dtrab) volumetric density, expressed as milligram hydroxyapatite per cubic
centimeter; trabecular bone volume fraction (BV/TV, in percent), trabecular number (TbN), trabecular thickness (TbTh, μm), trabecular separation
(TbSp, in micrometer), heterogeneity of the trabecular network (TbSp.SD), cross-sectional area (CSAtotal, in square millimeter), and cortical
thickness (CTh, in millimeter). Comparisons between ESRD patients and age-matched controls for continuous variables were performed with a
Wilcoxon matched-pairs signed-ranks test. Comparisons between ESRD patients and young healthy controls were performed with a Kruskal–
Wallis equality-of-populations rank test
* p<0.05 as compared with gender-matched young healthy controls; ** p<0.01 as compared with gender-matched young healthy controls;
*** p<0.05 as compared with age-, weight-, height-, and gender-matched controls; **** p<0.01 as compared with age-, weight-, and gender-matched
controls
NA not assessed
a For the “% Difference” variable, given the skewness and large range of the percent difference of cortical porosity, the median was computed
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agreement with our results insofar as we observed also
alterations in both cortical and trabecular compartments.
The capacity of HR-pQCT to discriminate between patients
with and without fractures in comparison to DXA in ESRD
patients was also recently reported [15]. Whilst all these
studies were cross-sectional, they often do not specify
whether the fractures occurred during the dialysis period
or previously. In our study, the number of fractures was very
low and precluded any firm conclusion to be drawn regard-
ing the potential of HR-pQCT results to predict fracture in
ESRD patients.
Both cortical and trabecular compartments were affected
and led to reduced bone strength, particularly in women,
irrespective of the skeletal site assessed. There were some
slight differences between distal radius and distal tibia,
which may be related to the small number of subjects, hence
to a limited power to detect significant differences. By
integrating all microstructural variables, FEA-determined
bone strength might be a more valid outcome to study the
consequences of ESRD on bone than isolated variables.
These results are similar to two recent publications [14,
15] and do not support the hypothesis of a selective cortical
bone deficit in dialysis patients.
Male ESRD patients displayed only a lower radius cortical
density. Indeed, they did not differ from age-matched healthy
controls for most aBMD and microstructure variables.
Table 4 Volumetric BMD, microstructural parameters, and cortical porosity in men and matched controls
ESRD patients Matched controls Young
controls
Value T-score Value T-score % Difference (95 % CI)
Radius Dtot (mg/cm3) 328±89 −0.7±1.5 346±58 −0.3±1.0 – 5 % (−22; 10) 366±58
Dcort (mg/cm3) 857±8**** −1.1±2.1 918±47 0.4±1.2 – 7 % (−10; −2) 902±40
CTh (mm) 0.82±0.3 −0.6±1.7 0.96±0.2 0.2±1.2 – 14 % (−33; 10) 0.92±0.17
Dtrab (mg/cm3) 181±54 −0.5±1.4 162±24 −1.1±0.7 16 % (−12; 33) 202±37
BV/TV (%) 15±5 −0.6±1.5 14±2 −1.1±0.7 14 % (−15; 30) 17±3
TbN (n/mm) 2.1±0.3 −0.1±1.3 1.9±0.2 −0.9±1.1 11 % (−2; 23) 2.1±0.2
TbTh (mm) 0.07±0.02* −0.8±1.8 0.07±0.01 −0.9±1.4 5 % (−25; 45) 0.08±0.01
TbSp (mm) 0.42±0.1 0.4±1.3 0.47±0.1 0.9±1.2 – 8 % (−19; −0.4) 0.40±0.06
TbSp.SD 0.19±0.1 0.8±2.9 0.20±0.1 1.0±1.8 1 % (−24; 5) 0.17±0.03
CSAtotal (mm2) 354±71 0.3±1.2 340±62 0.1±1.0 6 % (−12; 24) 334±61
Cortical porosity (%) 2.4±1.6 – 1.8±0.8 – 42 % (−16; 95) NA
Cortical pore diameter (mm) 0.16±0.03*** – 0.17±0.02 – – 4 % (−13; −2) NA
Tibia Dtot (mg/cm3) 277±60** −1.2±0.9 308±53 −0.7±0.8 – 7 % (−25; 3) 362±54
Dcort (mg/cm3) 867±66* −1.1±1.7 888±51 −0.6±1.3 – 2 % (−9; 4) 910±38
C.Th (mm) 1.2±0.3* −0.7±0.9 1.3±0.3 −0.3±0.8 – 8 % (31; 8) 1.4±0.3
Dtrab (mg/cm3) 149±50** −1.5±1.1 179±34 −0.9±0.8 – 11 % (−28; 15) 218±45
BV/TV (%) 14±3** −1.1±0.9 15±3 −0.8±0.7 – 4 % (−28; 18) 18±4
TbN (n/mm) 1.9±0.4* −0.9±1.3 1.9±0.3 −0.8±1.1 2 % (−16; 13) 2.1±0.3
TbTh (mm) 0.07±0.01** −1.8±1.2 0.08±0.01 −1.0±1.1 – 8 % (−19; 0) 0.09±0.01
TbSp (mm) 0.48±0.1* 1.5±2.1 0.46±0.1 1.2±1.8 10 % (−13; 23) 0.39±0.06
TbSp.SD 0.25±0.1** 1.9±3.5 0.21±0.1 1.1±1.4 27 % (−20; 35) 0.17±0.04
CSAtotal (mm2) 865±142 0.3±0.9 865±154 0.3±1.0 2 % (−9; 3) 824±158
Cortical porosity (%) 6.6±3.0 – 6.1±2.8 – 20 % (−28; 42) NA
Cortical pore diameter (mm) 0.19±0.02 – 0.19±0.02 – 1 % (−12; 11) NA
Values are means ± SD. Total (Dtot), cortical (Dcort), and trabecular (Dtrab) volumetric density, expressed as milligram hydroxyapatite per cubic
centimeter; trabecular bone volume fraction (BV/TV, in percent), trabecular number (TbN), trabecular thickness (TbTh, in micrometer), trabecular
separation (TbSp, in micrometer), heterogeneity of the trabecular network (TbSp.SD), cross-sectional area (CSAtotal, in square millimeter), and
cortical thickness (CTh, in millimeter). Comparisons between ESRD patients and matched controls for continuous variables were performed with a
Wilcoxon matched-pairs signed-ranks test. Comparisons between ESRD patients and young healthy controls were performed with a Kruskal–
Wallis equality-of-populations rank test
NA not assessed
* p<0.05 as compared with gender-matched young healthy controls; ** p<0.01 as compared with gender-matched young healthy controls;
*** p<0.05 as compared with age-, weight-, and gender-matched controls, **** p<0.01 as compared with age-, weight-, height-, and gender-matched
controls
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However, we cannot provide a convincing explanation to
account for the lack of differences between these two
populations. It remains to be elucidated whether this may
be due to the forces experienced by skeletal sites in men as
the latter were approximately 18 kg heavier than the wom-
en [40], or whether men are less likely to restrain upper
limbmovement during scan acquisition. Indeed, measurement
error with HR-pQCT at the radius is higher on average than
that at the tibia [41].
As explanatory mechanisms of ESRD-associated micro-
structural defects, we found a negative correlation between
cortical density and/or thickness and BALP, which empha-
sizes the role of bone turnover. Serum PTH is known to
affect bone turnover and is used for the noninvasive assess-
ment of bone turnover abnormalities in CKD-5D patients.
Second-generation assays measure not only the intact PTH,
but also several fragments, and it is well known that intact
PTH measurement cannot reliably diagnose bone turnover,
particularly when the range of serum PTH levels are within
the range of KDIGO guidelines [16]. In our study, we had
only few patients with very high PTH levels. However, one
of the salient and original findings is the significant corre-
lation between CtPo and KDIGO PTH level categories [42].
This observation is important since 80 % of our bone mass
is cortical and 80 % of all fractures occur in non-vertebral
sites that are mainly cortical. This change may be an impor-
tant contributor of skeletal fragility as the cortical compart-
ment supports a large majority of axial loads in the
peripheral skeleton [27, 43]. Data from histomorphometric
studies on CtPo in ESRD patients are scarce. In a study
recently performed by Malluche et al. in black and white
patients, it was shown that porosity was increased in 50 % of
whites. When both black and white patients were analyzed
together, CtPo was increased in patients with high bone
turnover and with deeper erosion depth. Both BALP and
serum PTH tended to be more elevated in patients with high
CtPo, but not significantly [44]. In an experimental model of
secondary hyperparathyroidism due to chronic renal failure
in rats, an excess of CtPo was not apparent until serum PTH
levels exceeded 500 pg/ml [45]. One hypothesis is that
serum PTH excess may increase CtPo through an increase
in bone turnover. To support this hypothesis, we observed a
positive correlation between the percentage of load carried
by the trabecular bone and BALP. Given the negative cor-
relation between cortical density and/or thickness and
BALP, this may reflect the negative impact of high bone
turnover on the cortical compartment.
Protein-energy wasting is common in end-stage renal
disease [46] and may affect 70–75 % of patients. Several
factors contribute to these deficiencies, such as anorexia,
increased protein catabolism, and reduced muscle synthesis,
all of multifactorial origin. We observed a positive associa-
tion between cortical density and nutritional status as
assessed by MNA-SF, and to our knowledge, this is the first
study to suggest that nutritional status may influence micro-
structural parameters in ESRD patients. We did not find,
however, a correlation with protein intake “per se.”
This study has several limitations. We studied a small
number of ESRD patients, but patients were compared to
well-matched controls and also to a young healthy popula-
tion. We wanted to recruit a young population which has
never been transplanted in order to capture the specific
effect of end-stage renal disease on bone and not the effect
of age or of corticosteroids. Unfortunately, recruitment goals
Table 5 Summary of calculated bone strength (finite-element analysis parameters and polar moment of inertia) by gender and site
Men Women
Dialyzed (n016) Controls (n016) Dialyzed (n017) Controls (n017)
Radius
Stiffness (N mm) 102,135±21,943 108,046±14,918 60,791±12,553** 74,255±14,246
Predicted failure load (N) 4,872±1,009 5,130±700 2,881±602** 3,556±662
% Load trabecular bone distal 65±15* 56±13 58±15* 49±10
Apparent modulus 1,877±577 2,051±288 1,629±298* 1,841±466
Polar area moment of inertia (mm4) 12,398±3,902 12,195±3,572 5,199±1,440* 7,534±4,731
Tibia
Stiffness (N mm) 242,876±50,986 270,769±49,746 165,528±35,369** 190,374±22,462
Predicted failure load (N) 11,680±2,372 12,818±2,293 7,969±1,628** 9,131±1,038
% Load trabecular bone distal 58±10 58±9 54±17 50±10
Apparent modulus 2,155±493 2,358±423 1,932±346 2,195±184
Polar area moment of inertia (mm4) 59,916±18,675 63,870±20,598 31,778±8,360 33,668±10,796
Values are mean ± SD
* p<0.05 as compared with age-, weight-, and gender-matched controls; ** p<0.01 as compared with age-, weight-, and gender-matched controls
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were not met in time. One of the reasons is that a young
population was rapidly referred for transplantation, and only
older potential participants were available. Another reason
was the unwillingness to be included in a clinical study. No
power calculation was done, as the study was initially
designed as exploratory. Thus, some differences have not
been detected due to a possible lack of power. HR-pQCT
provides an accurate evaluation of mineralized components,
but it does not allow the evaluation of non-mineralized
matrix. In addition, there were not enough patients with
low-trauma fractures to find differences in HR-pQCT
parameters between them and non-fractured controls.
However, in addition to standard HR-pQCT morphologic
outcomes, our study is strengthened by the assessment of
CtPo, and bone strength and stiffness estimated from
FEA. The studied patients were relatively young. There-
fore, the results need to be interpreted in regard to a
young ESRD population.
Table 6 Spearman's rank correlation coefficients of the association between bone microstructural parameters and demographic, dialysis,
nutritional, and biological parameters
R [p value]
Serum PTHa BALP BMI (kg/m2) MNA-SF Protein intake
(g/kg of body
weight)
Dialysis
duration
(years)
aBMD Lumbar spine BMD (g/cm2) −0.29 [0.10] −0.53 [0.01] 0.47 [0.01] 0.37 [0.04] −0.16 [0.37] 0.05 [0.79]
Total hip BMD (g/cm2) −0.01 [0.98] −0.32 [0.08] 0.37 [0.03] 0.35 [0.05] 0.10 [0.56] 0.23 [0.19]
Radius Dtot (mg/cm3) 0.09 [0.63] −0.26 [0.16] 0.21 [0.24] 0.22 [0.23] 0.06 [0.72] 0.11 [0.55]
Dcort (mg/cm3) 0.03 [0.85] −0.36 [0.05] 0.31 [0.08] 0.42 [0.02] 0.12 [0.52] −0.16 [0.38]
CTh (mm) 0.00 [0.99] −0.40 [0.03] 0.32 [0.07] 0.30 [0.10] 0.09 [0.60] 0.06 [0.76]
Dtrab (mg/cm3) 0.11 [0.53] −0.05 [0.81] 0.15 [0.40] 0.10 [0.57] −0.05 [0.79] 0.18 [0.31]
BV/TV (%) 0.12 [0.50] −0.20 [0.94] 0.13 [0.47] 0.09 [0.61] −0.06 [0.73] 0.18 [0.31]
TbN (n/mm) 0.03 [0.86] −0.19 [0.31] 0.27 [0.14] 0.21 [0.25] −0.15 [0.40] 0.10 [0.57]
TbTh (mm) 0.19 [0.30] 0.17 [0.37] 0.00 [1.00] 0.02 [0.93] 0.10 [0.59] 0.22 [0.22]
TbSp (mm) −0.05 [0.77] 0.15 [0.43] −0.22 [0.22] −0.22 [0.22] 0.12 [0.50] −0.10 [0.56]
CSAtotal (mm2) −0.19 [0.29] −0.21 [0.26] 0.05 [0.78] 0.10 [0.60] 0.10 [0.58] 0.12 [0.49]
TbSp.SD −0.20 [0.90] 0.20 [0.29] −0.26 [0.15] −0.31 [0.08] 0.16 [0.38] −0.15 [0.40]
Cortical porosity (%) 0.20 [0.27] 0.13 [0.49] 0.06 [0.73] −0.32 [0.07] −0.13 [0.49] 0.18 [0.31]
Stiffness (N mm) 0.05 [0.77] −0.35 [0.06] 0.21 [0.24] 0.18 [0.32] 0.13 [0.46] 0.09 [0.61]
Predicted failure load (N) −0.03 [0.86] −0.33 [0.07] 0.22 [0.22] 0.19 [0.29] 0.16 [0.39] 0.12 [0.50]
Tibia Dtot (mg/cm3) 0.09 [0.61] −0.25 [0.18] 0.25 [0.16] 0.28 [0.12] −0.06 [0.75] 0.08 [0.67]
Dcort (mg/cm3) 0.17 [0.34] −0.34 [0.06] 0.10 [0.58] 0.41 [0.02] 0.14 [0.42] −0.25 [0.16]
CTh (mm) 0.06 [0.73] −0.37 [0.04] 0.22 [0.22] 0.32 [0.07] −0.01 [0.96] −0.05 [0.78]
Dtrab (mg/cm3) 0.08 [0.64] −0.00 [0.99] 0.10 [0.57] −0.07 [0.71] −0.14 [0.42] 0.11 [0.54]
BV/TV (%) 0.01 [0.94] −0.14 [0.46] 0.24 [0.18] 0.07 [0.71] −0.15 [0.42] 0.10 [0.56]
TbN (n/mm) −0.08 [0.64] −0.22 [0.23] 0.40 [0.02] 0.03 [0.87] −0.28 [0.11] 0.10 [0.60]
TbTh (mm) 0.12 [0.51] 0.11 [0.55] −0.07 [0.70] −0.02 [0.93] 0.09 [0.63] −0.01 [0.95]
TbSp (mm) 0.07 [0.70] 0.22 [0.23] −0.37 [0.03] −0.05 [0.79] 0.24 [0.18] −0.11 [0.54]
CSAtotal (mm2) −0.12 [0.50] −0.28 [0.12] 0.19 [0.30] 0.09 [0.61] 0.10 [0.56] 0.02 [0.89]
TbSp.SD 0.11 [0.54] 0.27 [0.14] −0.40 [0.02] −0.15 [0.41] 0.28 [0.11] 0.20 [0.26]
Cortical porosity (%) −0.08 [0.68] 0.20 [0.28] 0.01 [0.96] −0.33 [0.06] −0.06 [0.72] 0.29 [0.11]
Stiffness (N mm) −0.02 [0.93] −0.40 [0.03] 0.35 [0.04] 0.28 [0.11] −0.02 [0.92] 0.04 [0.83]
Predicted failure load (N) 0.01 [0.95] −0.40 [0.03] 0.34 [0.05] 0.27 [0.13] −0.02 [0.93] 0.04 [0.84]
Significant coefficients of regression, beta (i.e., p<0.05) are italicized. The following variables, which are not significantly associated with any
independent variables, are not included in the table: calcium intake and serum IGF1 level. Total (Dtot), cortical (Dcort), and trabecular (Dtrab)
volumetric density, expressed as milligram hydroxyapatite per cubic centimeter; trabecular bone volume fraction (BV/TV, in percent), trabecular
number (TbN), trabecular thickness (TbTh, in micrometer), trabecular separation (TbSp, in micrometer), heterogeneity of the trabecular network
(TbSp.SD), cross-sectional area (CSAtotal, in square millimeter), and cortical thickness (CTh, in millimeter)
BALP Bone-specific alkaline phosphatase
a Based on a mean PTH value of two samples measured at 3-month intervals
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Conclusion
With the limitations due to a small number of patients
studied, the results indicate that trabecular and cortical bone
microstructure was altered in ESRD patients, as assessed by
HR-pQCT. This was predominantly found in women. These
changes translate into reduced bone strength and stiffness.
The cortical compartment appears to be influenced by the
level of bone turnover. Cortical porosity was related to
category levels of parathyroid hormone.
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